PFE - Pfizer Inc.

NYSE - Nasdaq Real-time price. Currency in USD
36.4648
-0.0252 (-0.0691%)
As of 11:45AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close36.3300
Open36.3900
Bid36.5800 x 1000
Ask36.5900 x 7000
Day's range36.3400 - 36.6900
52-week range31.6700 - 39.4300
Volume5,324,230
Avg. volume25,107,966
Market cap216.914B
Beta0.95
PE ratio (TTM)10.37
EPS (TTM)3.5170
Earnings date1 May 2018
Forward dividend & yield1.36 (3.74%)
Ex-dividend date2018-02-01
1y target est40.16
Trade prices are not sourced from all markets
  • Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
    Market Realist4 hours ago

    Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.

  • How Analysts View Tetraphase Pharmaceuticals in April 2018
    Market Realist20 hours ago

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.

  • A Look at the Financial Performance of Spark Therapeutics
    Market Realistyesterday

    A Look at the Financial Performance of Spark Therapeutics

    Spark Therapeutics (ONCE) generated revenue of $12 million in 2017 compared to $20.1 million in 2016. Under this collaboration, Spark Therapeutics maintains the responsibility for developing SPK-FIX candidates through Phase 1 and 2 trials. In November 2017, this agreement was amended, and Spark received a $10 million up-front payment and was eligible to receive an additional $15 million.

  • Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
    Market Realistyesterday

    Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

    Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.

  • Analysts’ Ratings for Achaogen and Peers in April 2018
    Market Realistyesterday

    Analysts’ Ratings for Achaogen and Peers in April 2018

    Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.

  • Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It
    Bloomberg2 days ago

    Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It

    Hours after markets closed on Bristol-Myers Squibb Co.’s worst day in more than a year, executives used a sugary analogy to explain to Wall Street why the drugmaker’s new cancer treatment would do just ...

  • 5 Drug Stocks Poised to Surpass on Earnings This Quarter
    Zacks2 days ago

    5 Drug Stocks Poised to Surpass on Earnings This Quarter

    The outlook for the upcoming first-quarter results looks bright.

  • Novartis’s 1Q18: Analysts Expect Revenue Growth
    Market Realist2 days ago

    Novartis’s 1Q18: Analysts Expect Revenue Growth

    Analysts expect Novartis’s (NVS) revenue to rise ~8.8% to $12.6 billion in 1Q18 following growth in operating revenues across all three of its segments during the quarter.

  • Updates on AbbVie’s AndroGel, Lupron, and Kaletra
    Market Realist2 days ago

    Updates on AbbVie’s AndroGel, Lupron, and Kaletra

    In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.

  • J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
    Zacks2 days ago

    J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

    J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

  • What Analysts Recommend for CymaBay Therapeutics
    Market Realist2 days ago

    What Analysts Recommend for CymaBay Therapeutics

    CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.

  • Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets
    Motley Fool2 days ago

    Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets

    One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.

  • Analysts’ Recommendations for Johnson & Johnson on April 16
    Market Realist3 days ago

    Analysts’ Recommendations for Johnson & Johnson on April 16

    Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.

  • Johnson & Johnson’s Revenue Estimates for 1Q18
    Market Realist3 days ago

    Johnson & Johnson’s Revenue Estimates for 1Q18

    As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

  • What to Expect from Johnson & Johnson’s 1Q18 Earnings
    Market Realist3 days ago

    What to Expect from Johnson & Johnson’s 1Q18 Earnings

    Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17Johnson & Johnson’s estimates

  • GlobeNewswire3 days ago

    Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco — Future Expectations, Projections Moving into 2018

    NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
    Investor's Business Daily6 days ago

    Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz

    Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks6 days ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

  • Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
    Zacks6 days ago

    Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug

    Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.

  • Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
    Zacks6 days ago

    Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

    Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

  • Asian stocks mostly up after Wall Street finishes higher
    Associated Press6 days ago

    Asian stocks mostly up after Wall Street finishes higher

    Asian stock markets were mostly higher Friday following overnight gains on Wall Street. Risk sentiment returned as the U.S. explores the possibility of returning to trade talks with 11 Pacific countries ...

  • Dow Jones Component Pfizer Isn't Interested In Bristol — Yet
    Investor's Business Daily7 days ago

    Dow Jones Component Pfizer Isn't Interested In Bristol — Yet

    Dow Jones component Pfizer has no interest in acquiring rival Bristol Myers Squibb — at least not yet, an analyst reportedly said Thursday.

  • Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
    Bloomberg7 days ago

    Pfizer's Deal Potential Doesn't Stop at Bristol-Myers

    From Eli Lilly to Celgene, there are several other options it could consider.

  • Pfizer Advances in Cancer Cell Therapy with Allogene Agreement
    Market Realist7 days ago

    Pfizer Advances in Cancer Cell Therapy with Allogene Agreement

    On April 10, 2018, Pfizer (PFE) announced that it has finalized its agreement with biotechnology company Allogene Therapeutics for Pfizer’s allogeneic CAR-T (chimeric antigen receptor T cells) therapy asset portfolio. Pfizer entered into the agreement on April 3, 2018, for the development of cancer cell therapies. According to the terms of the agreement, upon completion of the transaction, Allogene has rights to Pfizer’s 16 pre-clinical CAR-T assets.

  • Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study
    Market Realist7 days ago

    Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study

    On April 11, 2018, Pfizer (PFE) stock witnessed a muted performance after its late-stage kidney trial for Inlyta failed to show any statistically significant improvement in disease-free survival compared to the placebo. The Phase III ATLAS trial evaluated the use of Inlyta (axitinib) as an adjuvant treatment for patients at high risk of RCC (renal cell carcinoma) recurrence after a nephrectomy.